PF-Atlas › Клинические испытания › NCT05513950
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody in Patients With IPF .
CHF10067 starting dose -- 1000mg · Фаза 1
ID реестра
NCT05513950
Фаза
Фаза 1
Статус
Завершено
Препарат / вмешательство
CHF10067 starting dose -- 1000mg (Cohort A)
Спонсор
Chiesi Farmaceutici S.p.A.
Начало
2023-01-25
Набор участников
52
Центры
9
Об исследовании
Assess the safety of CHF10067 (study drug) and any side effects that might be associated with it. The study also evaluated how much of the study drug gets into the bloodstream and how long the body takes to remove it. The body's immune response to the study drug was evaluated. Chiesi conducted this study in patients affected by idiopathic pulmonary fibrosis (IPF, a progressive and chronic lung disease). Chiesi performed this study to establish the drug doses that would be suitable for future studies (a dose finding study).
Связанные материалы
Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT05513950 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.